Clinical trials: Androgen Deprivation Therapy
Prostate Cancer
Living Well on Androgen Deprivation Therapy
Approximately half of men treated for prostate cancer will be offered hormone deprivation therapy during their cancer experience.
- Trial name
- NCT02108613
- Testing
- Exercise Sessions, Nutrition Education, Peer Support Volunteer
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Covid19
EAT-DUTA AndroCoV Trial
During the continuing SARS-CoV-2 (COVID-19) pandemic, several studies have reported a significant difference in the rate of severe cases between adult females and adult males (42% vs 58%).
- Trial name
- NCT04729491
- Testing
- Dutasteride 0.5 mg, Azithromycin, Nitazoxanide
- Where
- Brazil
- Volunteers
- 138 people
- Sponsor
- Corpometria Institute
Prostate Cancer
Med Diet Prevention Metabolic Syndrome Men Undergoing Androgen Deprivation Therapy Prostate Cancer
The purpose of this study is to assess for changes in a patient's overall energy level and well-being (quality of life) after 8 weeks of dietary intervention.
- Trial name
- NCT01083771
- Testing
- Olive Oil
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Brown University
Prostatic Neoplasms
A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases
Main Study: The purpose of main study is to assess if the combination of apalutamide and androgen deprivation therapy (ADT) in participants with high-risk localized prostate cancer improves the biochemical recurrence (BCR) free…
- Trial name
- NCT04523207
- Testing
- Apalutamide, ADT, Relugolix
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Janssen Research & Development, LLC
Neoadjuvant Therapy \High Risk Prostate Cancer
Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy（ADT）for High Risk Prostate Cancer
This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Proxalutamide combined with androgen deprivation therapy（ADT）for High risk prostate cancer ，This trial is A randomized, controlled, double-blind…
- Trial name
- NCT05076851
- Testing
- Proxalutamide
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Hongqian Guo
Castration-resistant Prostate Cancer, Metastatic Cancer
Predictive Nomogram of CRPC
This is an observational, prospective (study following participants forward in time), multi-center (study conducted in more than 1 center) study to identify the risk factors, then develop and validate the predictive Nomogram of…
- Trial name
- CRPC-PN (NCT03177551)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Second Hospital
Osteoporosis
Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
The aim of this study is to determine the long term effects of two types of hormonal treatment for advanced prostate cancer (LHRH agonists and the antiandrogen bicalutamide)on the bone mineral density of patients.
- Trial name
- NCT00536653
- Testing
- Bicalutamide and Calcium/ Vitamin D supplementation, LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation, LHRH agonists (Goserelin acetate)
- Where
- United Kingdom
- Volunteers
- 618 people
- Sponsor
- Wirral University Teaching Hospital NHS Trust
Prostate Cancer
The Effect of ADT on PSMA-PET.
Phase A: To describe and to determine the maximum standardised uptake values (SUV) in prostate specific membrane antigen positron emission tomography (PSMA-PET) before ADT and 7, 14 and 28 days after ADT.
- Trial name
- ADTPSMA (NCT03313726)
- Testing
- GnRH antagonist
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Turku University Hospital
Prostate Cancer
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells.
- Trial name
- NCT00002855
- Testing
- Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Factors Affecting Androgen Deprivation Therapy Choice in Prostate Cancer Patients
The objective of this study is to investigate possible factors that will affect the choice of androgen deprivation therapy in prostate cancer patients.
- Trial name
- NCT05202340
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- Chinese University of Hong Kong
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and…
- Conditions
- Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
- Trial name
- NCT05617885
- Testing
- Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Praful Ravi, MB BCHir, MRCP
Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
The goal of this clinical trial is to evaluate whether the addition of pelvic radiotherapy to androgen deprivation therapy (ADT) can delay disease progression and improve survival outcomes in patients with pathologically…
- Conditions
- Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
- Trial name
- RADVAN (NCT07477626)
- Testing
- Androgen Deprivation Therapy (ADT), radiotherapy
- Where
- 13 sites in China
- Volunteers
- 372 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer
A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer
The purpose of this open-label, single-arm, multicenter, post-marketing trial is to evaluate long-term safety of Firmagon® in approximately 230 Indian patients diagnosed with advanced hormone-dependent prostate cancer requiring…
- Trial name
- NCT02726009
- Testing
- Degarelix
- Where
- 19 sites in India
- Volunteers
- 230 people
- Sponsor
- Ferring Pharmaceuticals
Metastatic Hormone-Sensitive Prostate Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in participants with mHSPC.
- Trial name
- NCT04191096
- Testing
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 234 sites in United States, Australia and 27 more
- Volunteers
- 1,251 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostatic Cancer
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten…
- Trial name
- UROCOR (NCT01284608)
- Where
- 33 sites in Spain
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Prostate Adenocarcinoma, Stage IIA Prostate Cancer
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
This randomized phase II trial studies the side effects and how well giving leuprolide acetate or goserelin acetate works compared to observation in treating patients with high-risk prostate cancer who have undergone radical…
- Conditions
- Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT00937768
- Testing
- Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Prostate Cancer Locally Advanced
Hypofractionated Radiotherapy With Magnetic Resonance Imaging-Guided Focal Boost and Pelvic Irradiation in High-Risk Prostate Cancer
This study evaluated long-term disease control and side effects of a moderately hypofractionated radiotherapy protocol for men with high-risk prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Locally Advanced, Prostatic Neoplams
- Trial name
- NCT07900555
- Testing
- Hypofractionated IMRT with focal simultaneous integrated boost and elective pelvic irradiation, Androgen Deprivation Therapy (ADT)
- Where
- Norway
- Volunteers
- 191 people
- Sponsor
- Haukeland University Hospital
Prostate Cancer
Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
The purpose of this study is to determine whether DCVAC/PCa added onto hormone therapy can improve PSA progression times for patients with Metastatic Prostate Cancer.
- Trial name
- NCT02107391
- Testing
- Dendritic Cells DCVAC/PCa, Leuprolide acetate, Goserelin Acetate
- Where
- 9 sites in Czechia
- Volunteers
- 63 people
- Sponsor
- SOTIO a.s.
Prostatic Neoplasms
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
The goal of this study is to find out if patients with prostate cancer being treated with the medications abiraterone and prednisone can discontinue hormone injections (examples include leuprolide, goserelin, triptorelin and…
- Trial name
- NCT03565835
- Testing
- Abiraterone Acetate, Prednisone
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Montefiore Medical Center
Prostate Cancer
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.
- Trial name
- NCT00089674
- Testing
- AMG 162
- Volunteers
- 1,468 people
- Sponsor
- Amgen